Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M

Psychedelics biotech Cybin Inc. CYBN closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units issued at a price of $0.34 each, for total aggregate gross proceeds of $8,250,000.

Each of these units equate one common share and one common share purchase warrant, the latter being exercisable to acquire one of the former for $0.40 during 60 months.

Units were offered in all Canadian provinces except Quebec and in the U.S., pursuant to a prospectus supplement to Cybin’s short-form base shelf prospectus dated July 5, 2021. The supplement will be filed with the SEC as part of a registration statement on Form F-10. 

Cantor Fitzgerald acted as the sole book-running manager, and A.G.P./Alliance Global Partners as its lead manager. In consideration for their services, the company paid a cash commission of $378,778 to the underwriters.

Following the offering, Cybin notified LPC fund of its intention to suspend common share purchases [top issuance set at $30 million worth] under its May-dated agreement effective immediately. The company reportedly sold an equivalent of $465,273 under the agreement prior to the suspension of sales. 

Cybin is set to use the net proceeds for corporate and working capital but mainly to progress CYB003 and CYB004’s pathways forward. 

See Also: COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'

These clinical programs (see more in depth HERE) consist of using novel psilocybin and DMT deuterated analogs to target the treatment of Major Depressive Disorder (MDD) and anxiety disorder, respectively. 

Yes we cover psychedelics, but we also truly own an expertise in the cannabis world! If you still haven’t heard about our biannual crowd-puller Cannabis Capital Conference, come join us and see it for yourself!

This September 27-28, the epicenter of cannabis investment and branding is coming to Chicago. Come get your deals done at our 17th CCC edition. Tickets HERE.

Photo: Benzinga edit with photo by PublicDomainPictures and sergeitokmakov on Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsPenny StocksPsychedelicsGuidanceFinancingManagementMarketsPsychedelic-Assisted TherapiesPsychedelics FinancingPublic Offering
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.


Loading...